Fusion Pharmaceuticals Inc.

NasdaqGS:FUSN 주식 보고서

시가총액: US$1.8b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Fusion Pharmaceuticals 관리

관리 기준 확인 4/4

Fusion Pharmaceuticals' CEO는 John Valliant, Dec2014 에 임명되었습니다 의 임기는 9.5 년입니다. 총 연간 보상은 $ 2.08M, 28.7% 로 구성됩니다. 28.7% 급여 및 71.3% 보너스(회사 주식 및 옵션 포함). 는 $ 6.86M 가치에 해당하는 회사 주식의 0.37% 직접 소유합니다. 6.86M. 경영진과 이사회의 평균 재임 기간은 각각 2.8 년과 5.2 년입니다.

주요 정보

John Valliant

최고 경영자

US$2.1m

총 보상

CEO 급여 비율28.7%
CEO 임기9.5yrs
CEO 소유권0.4%
경영진 평균 재임 기간2.8yrs
이사회 평균 재임 기간5.2yrs

최근 관리 업데이트

Recent updates

Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook

Mar 03

Health Check: How Prudently Does Fusion Pharmaceuticals (NASDAQ:FUSN) Use Debt?

Jan 30
Health Check: How Prudently Does Fusion Pharmaceuticals (NASDAQ:FUSN) Use Debt?

Fusion Pharmaceuticals initiated at buy at Truist on lead candidate for solid tumors

Sep 16

Fusion Pharma doses first patient in phase 1/2 study for solid tumors treatment

Aug 29

Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?

Aug 10
Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?

Fusion Pharmaceuticals GAAP EPS of -$0.44 beats by $0.09, revenue of $0.57M beats by $0.46M

Aug 09

Fusion Pharma wins FDA nod to start trials for solid tumor candidate

Jun 23

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Jan 16
We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Aug 28
We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Fusion Pharma trades higher on early-stage data for cancer therapy

Jun 14

We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely

Apr 05
We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely

How Much Of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Do Institutions Own?

Mar 01
How Much Of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Do Institutions Own?

Who Has Been Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Shares?

Jan 25
Who Has Been Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Shares?

Here's Why We're Not Too Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Situation

Dec 21
Here's Why We're Not Too Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Situation

Fusion Pharmaceuticals EPS misses by $0.04

Nov 10

Fusion Pharma teams up with AstraZeneca in next-gen radiopharmaceuticals for cancer

Nov 02

CEO 보상 분석

John Valliant 의 보수는 Fusion Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$104m

Dec 31 2023US$2mUS$597k

-US$95m

Sep 30 2023n/an/a

-US$91m

Jun 30 2023n/an/a

-US$98m

Mar 31 2023n/an/a

-US$92m

Dec 31 2022US$3mUS$595k

-US$88m

Sep 30 2022n/an/a

-US$80m

Jun 30 2022n/an/a

-US$76m

Mar 31 2022n/an/a

-US$83m

Dec 31 2021US$3mUS$597k

-US$81m

Sep 30 2021n/an/a

-US$77m

Jun 30 2021n/an/a

-US$68m

Mar 31 2021n/an/a

-US$86m

Dec 31 2020US$7mUS$505k

-US$80m

Sep 30 2020n/an/a

-US$75m

Jun 30 2020n/an/a

-US$65m

Mar 31 2020n/an/a

-US$24m

Dec 31 2019US$1mUS$399k

-US$16m

보상 대 시장: John 의 총 보상 ($USD 2.08M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 5.67M ).

보상과 수익: John 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

John Valliant (53 yo)

9.5yrs

테뉴어

US$2,081,586

보상

Dr. John F. Valliant Ph D, is Founder of Fusion Pharmaceuticals Inc. and its Chief Executive Officer & Director since December 2014. He served as Member of Scientific Advisory Board of Molecular Insight Ph...

리더십 팀

이름위치테뉴어보상소유권
John Valliant
Founder9.5yrsUS$2.08m0.37%
$ 6.9m
Mohit Rawat
President & Chief Business Officer2.8yrsUS$1.41m0.015%
$ 276.8k
John Crowley
CFO & Compliance Officer5.3yrsUS$1.30m0.012%
$ 224.4k
Eric Burak
Chief Technology Officer2.6yrsUS$1.42m0.045%
$ 829.5k
Christopher Leamon
Chief Scientific Officer2.6yrs데이터 없음0.014%
$ 257.7k
Amanda Cray
Senior Director of Investor Relations & Corporate Communicationsno data데이터 없음데이터 없음
Maria Stahl
Chief Legal Officer3.8yrs데이터 없음데이터 없음
Eric Hoffman
Senior Vice President of Business Development2.8yrs데이터 없음데이터 없음
Cara Ferreira
Chief of Staffno data데이터 없음데이터 없음
Joanne Schindler
Executive Vice President of Medical Director & Clinical Development2.2yrs데이터 없음데이터 없음
Dmitri Bobilev
Chief Medical Officer1.6yrs데이터 없음데이터 없음

2.8yrs

평균 재임 기간

53.5yo

평균 연령

경험이 풍부한 관리: FUSN 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
John Valliant
Founder9.5yrsUS$2.08m0.37%
$ 6.9m
Barbara Duncan
Independent Chairperson of the Board3.7yrsUS$126.49k0%
$ 0
Pablo Cagnoni
Independent Director4.5yrsUS$103.49k0%
$ 0
Steven Gannon
Independent Director4.4yrsUS$108.24k0.066%
$ 1.2m
Jeremy Bender
Independent Directorless than a yearUS$101.89k0%
$ 0
Deepak Khuntia
Member of Advisory Board5.9yrs데이터 없음데이터 없음
Donald Bergstrom
Independent Director3.2yrsUS$98.49k0%
$ 0
Geoffrey Shapiro
Member of Advisory Board5.9yrs데이터 없음데이터 없음
Rosalyn Juergens
Member of Advisory Board5.9yrs데이터 없음데이터 없음
Gillies O'Bryan-Tear
Member of Advisory Board5.9yrs데이터 없음데이터 없음
Oliver Sartor
Member of Advisory Board5.9yrs데이터 없음데이터 없음
Philina Lee
Independent Director3.3yrsUS$97.49k0%
$ 0

5.2yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 이사회: FUSN 의 이사회는 경험(평균 재직 기간 5.2 년)으로 간주됩니다.